دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Adverse Effects of Low?Dose Methotrexate in a Randomized Double?Blind Placebo?Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial
Kathleen M.M. Vanni Nancy Berliner Nina P. Paynter Robert J. Glynn Jean MacFadyen Joshua Colls Fengxin Lu Chang Xu Paul M. Ridker Daniel H. Solomon
doi : 10.1002/acr2.11187
Volume2, Issue12 December 2020 Pages 697-704
Low?dose methotrexate (LD?MTX), a cornerstone in the treatment of rheumatoid arthritis, is associated with a moderately increased risk of anemia, leukopenia, and skin cancers, but the risks of myelosuppression and malignancy during LD?MTX use remain incompletely described. We examined the risks of cytopenias and skin cancers among patients taking LD?MTX versus placebo in a large randomized controlled trial (RCT).
Codevelopment of Patient Self?Examination Methods and Joint Count Reporting for Rheumatoid Arthritis
Rebecca Grainger Hermaleigh R. Townsley Simon Stebbings Andrew A. Harrison William J. Taylor Lisa K. Stamp
doi : 10.1002/acr2.11197
Volume2, Issue12 December 2020 Pages 705-709
To determine whether training increases accuracy of self?reported joint counts in people with rheumatoid arthritis (RA) and describe the knowledge and techniques for self?examination of joints for reporting of RA disease activity.
Depressive Symptoms and the Effectiveness of a Urate?Lowering Therapy in a Clinical Trial
Sylvie Mrug Catheryn Orihuela Elizabeth Rahn Amy Mudano Jeffrey Foster Kenneth Saag Angelo Gaffo
doi : 10.1002/acr2.11192
Volume2, Issue12 December 2020 Pages 710-714
This ancillary study examined the impact of depressive symptoms on the effectiveness of a urate?lowering therapy in the context of a clinical trial.
Trends in Hospitalization Rates, Major Causes of Hospitalization, and In?Hospital Mortality in Rheumatoid Arthritis in the United States From 2000 to 2014
Priyanka Iyer Yubo Gao Elizabeth H. Field Jeffrey R. Curtis Charles F. Lynch Mary Vaughan?Sarrazin Namrata Singh
doi : 10.1002/acr2.11200
Volume2, Issue12 December 2020 Pages 715-724
To evaluate national trends in hospitalizations and in?hospital mortality in rheumatoid arthritis (RA).
Patient Perspectives on Gout and Gout Treatments: A Patient Panel Discussion That Informed the 2020 American College of Rheumatology Treatment Guideline
Jasvinder A. Singh Tuhina Neogi John D. FitzGerald
doi : 10.1002/acr2.11199
Volume2, Issue12 December 2020 Pages 725-733
The objective of this study was to understand patient perspectives to inform the voting process for the 2020 American College of Rheumatology (ACR) gout treatment guideline.
Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function
Anna?Maria Liphardt Eva Manger Sonja Liehr Lisa Bieniek Arnd Kleyer David Simon Koray Tascilar Michael Sticherling Jürgen Rech Georg Schett Axel J. Hueber
doi : 10.1002/acr2.11196
Volume2, Issue12 December 2020 Pages 734-740
The objective of this study was to compare the impact of psoriatic disease (psoriatic arthritis [PsA] and psoriasis) and rheumatoid arthritis (RA) on objective and subjective parameters of hand function.
The Impact of Self?Efficacy on Activity Limitations in Patients With Hip Osteoarthritis: Results From a Cross?Sectional Study
Theresa Bieler Thomas Anderson Nina Beyer Susanne Rosth?j
doi : 10.1002/acr2.11198
Volume2, Issue12 December 2020 Pages 741-749
Pain and activity limitations are the main health complaints in osteoarthritis. We explored pathways between pain and activity limitations in a chain mediation model that involved self?efficacy, physical activity behavior, and muscle function in patients with hip osteoarthritis not awaiting hip replacement.
Stakeholder Development of an Online Program to Track Arthritis?Related Patient?Reported Outcomes Longitudinally: Live Yes! INSIGHTS
Karen E. Schifferdecker Rebecca L. Butcher Erin Knight Emily Creek M. Suzanne Schrandt Laura Marrow Marie Jaffe Arlene Vinci Guy Eakin
doi : 10.1002/acr2.11203
Volume2, Issue12 December 2020 Pages 750-759
Patient?reported outcome measures (PROMs) are increasingly used in clinical settings but may not provide benefits to patients outside of health encounters. The Arthritis Foundation’s Live Yes! Network provides an opportunity for PROM use by individuals and the network that assists individuals with managing their arthritis between encounters. Our objective was to develop a patient?reported outcomes platform for the network, Live Yes! INSIGHTS, using mixed methods and extensive stakeholder input.
Rise and Fall: Hydroxychloroquine and COVID?19 Global Trends: Interest, Political Influence, and Potential Implications
Tessa R. Englund Alan C. Kinlaw Saira Z. Sheikh
doi : 10.1002/acr2.11207
Volume2, Issue12 December 2020 Pages 760-766
The coronavirus disease 2019 (COVID?19) pandemic has led to rapid research and reporting on potential preventatives and treatments for the disease, including the drug hydroxychloroquine (HCQ). Despite a lack of robust evidence to support the use of HCQ for treatment of COVID?19, it was publicly endorsed and received widespread media coverage and public interest. The purpose of this report is to describe and contextualize the surges in public interest, demand, and adoption of HCQ for treatment of COVID?19 and outline implications for future public health policy and practice.
